Trials / Terminated
TerminatedNCT03994705
Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma
Phase I Safety Study of Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Cartesian Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This Phase I study will test the safety and anti-myeloma activity of ascending doses of Descartes-11 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible patients with active multiple myeloma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Descartes-11 | CAR T-Cells |
| DRUG | Fludarabine | Pre-conditioning chemotherapy |
| DRUG | Cyclophosphamide | Pre-conditioning therapy |
Timeline
- Start date
- 2019-08-01
- Primary completion
- 2021-05-27
- Completion
- 2021-06-11
- First posted
- 2019-06-21
- Last updated
- 2025-05-15
- Results posted
- 2025-04-25
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03994705. Inclusion in this directory is not an endorsement.